The agreement does not currently apply to veterinary medicines, but the EU and FDA have agreed that veterinary drugs will be included by 15 December 2019 and discussions have already taken place between technical experts. The transition period for medicines for human use, which is covered by the agreement, ended on 11 July 2019: trade agreements are trade agreements designed to facilitate market access and promote greater international harmonization of compliance standards while protecting consumer safety. The agreement, initially announced in 2017, represents a three-year cooperation between the FDA and the EU and will allow all partners to recognise inspections carried out by each other. When we first discussed with the European Union the prospects of a mutual recognition agreement in which EU member state regulators (EUMS) and the FDA would agree to rely on the actual conclusions of their good manufacturing practices (GMPs) of pharmaceutical companies, the potential benefits seemed obvious. These agreements benefit regulators by reducing dual controls in any other area, allowing for a greater focus on sites likely to be at higher risk and increased coverage of global supply chain inspections. We certainly agree that there is a need for more data on the MRA us/EU, beyond the operational data we are currently collecting. In fact, we are working with our EU partners to look at what additional measures might be instructive. With sufficient data, the FDA will decide how we assume not only our inspection resources, but also the extent and scope of future mutual recognition and mutual trust agreements that could include other categories of inspections and types of products such as veterinary drugs. Since these other categories in Europe often involve different inspections than those tested for drugs for human use, implementation may take some time.
Finally, with the necessary measures, we could also confirm its usefulness, so that manufacturers can avoid unnecessary inspections while ensuring that the drugs are safer for patients. EMA: www.ema.europa.eu/en/documents/other/questions-answers-impact-mutual-recognition-agreement-between-european-union-united-states-11-july_en.pdf The European Union (EU) and the United States have concluded a comprehensive Mutual Recognition Agreement (MRA) following the recognition of Slovakia by the U.S. Food and Drug Administration (FDA). The MRA will allow both organizations to rely on inspections of production sites for certain drugs for human use in their respective territories. The European Union (EU) has signed Mutual Recognition Agreements (MRA) with third-country authorities on the assessment of compliance of regulated products. These agreements contain a sectoral annex on mutual recognition of good manufacturing practice inspections (GMPs) and certification of batches of medicines for human and veterinary use. We await the final decision to include veterinary medicines in the scope of the mutual recognition agreement currently concluded between the European Community (EU) and the United States, which allows the recognition of GMP inspections in other Member States.